Monoclonal Antibodies Targeting Tau Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tau-related diseases, such as Alzheimer's, lack effective methods to inhibit tau aggregation and deposition, which contribute to neuronal damage and cognitive decline.
Innovation Solution
Development of isolated monoclonal antibodies that specifically bind to tau, targeting epitopes within specific amino acid residues, competing with or binding to the same epitopes as antibody 16G7, and comprising humanized, chimeric, or veneered forms to effectively inhibit tau aggregation and deposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for tau-related diseases, then existing therapeutic approaches are maintained, but effective inhibition of tau aggregation and deposition is not achieved
Solution Approach 1:
Monoclonal antibodies serve as intermediary molecules that specifically bind to tau protein, blocking its aggregation and deposition. The antibodies act as mediators between the therapeutic goal and the pathological tau protein, preventing harmful interactions and promoting clearance of aggregated tau through phagocytosis.
Solution Approach 2:
The invention changes the biochemical parameters of tau by introducing antibodies that alter its aggregation state. The antibodies modify the physical-chemical properties of tau by binding to specific epitopes, preventing the conformational changes and intermolecular interactions that lead to pathological aggregation and deposition.
2Reliability
If monoclonal antibodies are developed to specifically bind tau, then tau aggregation is inhibited, but the complexity of antibody development and production increases
Solution Approach 1:
The antibody development process is segmented into distinct stages: identification of specific tau epitopes (such as the microtubule-binding region), generation of candidate monoclonal antibodies, screening for aggregation-inhibiting activity, and optimization of binding specificity. This segmentation allows systematic progression from general antibody production to highly specific tau-targeting antibodies.
Solution Approach 2:
The antibodies are designed to target specific local regions (epitopes) on the tau protein, particularly the microtubule-binding region. By focusing binding specificity on particular amino acid sequences rather than the entire tau protein, the antibodies achieve high specificity while reducing off-target effects and simplifying development through epitope-focused screening.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies reduce tau aggregation, inhibit its inter- and intracellular transmission, and induce phagocytosis, thereby slowing disease progression and treating or preventing tau-related diseases like Alzheimer's.
Implementation Method 1
isolated monoclonal antibody that specifically binds to tau
Implementation Method 2
induce phagocytosis, thereby slowing disease progression
Data Source
AI summary
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.